The present invention relates to a novel use of a sesquiterpene derivative, and more specifically, an intraocular blood vessel containing, as an active ingredient, a sesquiterpene derivative compound represented by Chemical Formula 1 of the present invention or a pharmaceutically acceptable salt thereof. The present invention relates to a composition for preventing, improving or treating macular degeneration or macular edema due to leakage. Although there are inconveniences and pain and side effects caused by commercially available therapeutic agents related to intraocular diseases directly into the vitreous cavity, the compounds of the present invention are administered by routes other than intravitreal administration (oral administration, peritoneal cavity) Even through injection, etc., it is distributed to the target organization (eye) and has a therapeutic effect regardless of the administration route, so it exhibits an excellent effect. [Selection] Figure 4【解決手段】本発明はセスキテルペン誘導体の新規な用途に関し、より詳しくは本発明の化学式１で表示されるセスキテルペン誘導体化合物又はその薬学的に許容可能な塩を有効成分として含む、眼球内血管漏出による黄斑変性又は黄斑浮腫の予防、改善又は治療用組成物に関する。市販の眼球内疾患関連治療剤が硝子体腔内に直接投与しなければならない不便とこれによる苦痛及び副作用があるが、本発明の化合物は硝子体腔内投与以外の他の投与経路（経口投与、腹腔注射など）を介してもターゲット組職（眼）に分布し、投与経路にかかわらず治療効能を有するので優れた効果を発揮する。【選択図】 図４
